A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

ClinicalTrials.gov ID: NCT06465069

Public ClinicalTrials.gov record NCT06465069. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 4, 2026, 4:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

Study identification

NCT ID: NCT06465069
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 420 participants

Conditions and interventions

Conditions

Interventions

LY4052031 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2024
Primary completion: Apr 30, 2027
Completion: Apr 30, 2027
Last update posted: Apr 19, 2026

2024 – 2027

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010-0269	Recruiting
Sarah Cannon Research Institute at HealthOne	Denver	Colorado	80218	Recruiting
Florida Cancer Specialists and Research Institute	St. Petersburg	Florida	33705	Recruiting
University of Chicago Hospital	Chicago	Illinois	60637	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02215	Recruiting
START Midwest Cancer and Hematology Centers of W Michigan	Grand Rapids	Michigan	49546	Recruiting
Washington University School of Medicine in St. Louis	St Louis	Missouri	63110	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029-6574	Recruiting
Columbia University Irving Medical Center	New York	New York	10032-3729	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Sarah Cannon Research Institute	Nashville	Tennessee	37203	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030-4000	Recruiting
South Texas Accelerated Research Therapeutics (START)	San Antonio	Texas	78229	Recruiting
University of Utah - Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting
START Mountain Region	West Valley City	Utah	84119	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06465069, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 19, 2026 · Synced May 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06465069 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →